Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of influenza vaccine immune response measurements in venous blood, finger-prick blood, and saliva
NL-OMON61540Not yet recruiting
- Sponsor
- Danone
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of ARCT-2138 in influenza, sponsored by Danone. Primary endpoint: Influenza antibody level agreement between finger-prick and venous blood. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
ARCT-2138
03
Conditions
influenza
Beyond the preview
Go deeper on NL-OMON61540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61540.